Investor Presentation July 31, 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2025 guidance, strategic and growth opportunities, other expectations and other non-historical information. Without limiting the foregoing, statements including the words "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "believe, ...

[Executive Summary & Q2 2025 Performance Highlights](index=1&type=section&id=Executive%20Summary%20%26%20Q2%202025%20Performance%20Highlights) [Second Quarter 2025 Financial Performance Overview](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Performance%20Overview) Omnicell exceeded Q2 2025 guidance for revenues, non-GAAP EBITDA, and EPS, raising full-year 2025 guidance - Omnicell exceeded Q2 2025 guidance for **revenues, non-GAAP EBITDA, and non-GAAP EPS**[1](index=1&type=chunk) - The company raised its full-year 2025 guidance for **total revenues, non-GAAP EBITDA, and non-GAAP EPS**[1](index=1&type=chunk) [Strategic and Operational Highlights](index=1&type=section&id=Strategic%20and%20Operational%20Highlights) The company experienced broad demand for solutions, especially connected devices, and introduced MedTrack RFID Line and MedVision innovations - Strong demand observed across solutions, with notable strength in **point-of-care connected devices** (XT Series automated dispensing cabinets, XTExtend console)[2](index=2&type=chunk) - Introduced new innovations: MedTrack RFID Line and MedVision inventory management solution[2](index=2&type=chunk) [Financial Results](index=1&type=section&id=Financial%20Results) [Second Quarter 2025 Financial Performance](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Performance) Omnicell's Q2 2025 total revenues increased 5%, driven by connected devices and services, with GAAP net income and EPS up, and non-GAAP metrics slightly down Q2 2025 vs Q2 2024 Financial Performance | Metric | Q2 2025 | Q2 2024 | Change (YoY) | | :----------------------- | :---------- | :---------- | :----------- | | Total Revenues | $291 million | $277 million | +5% ($14 million) | | GAAP Net Income | $6 million | $4 million | +$2 million | | GAAP Diluted EPS | $0.12 | $0.08 | +$0.04 | | Non-GAAP Net Income | $21 million | $24 million | -$3 million | | Non-GAAP Diluted EPS | $0.45 | $0.51 | -$0.06 | | Non-GAAP EBITDA | $38 million | $40 million | -$2 million | - The year-over-year increase in total revenues was driven by strength in connected devices, technical services, SaaS and Expert Services, and consumables revenues[3](index=3&type=chunk) [Balance Sheet Snapshot](index=1&type=section&id=Balance%20Sheet%20Snapshot) As of June 30, 2025, Omnicell maintained a strong liquidity position with significant cash and available credit, alongside manageable debt levels Balance Sheet as of June 30, 2025 | Metric | Amount | | :-------------------- | :----------- | | Cash and Cash Equivalents | $399 million | | Total Debt (net) | $342 million | | Total Assets | $2.1 billion | | Revolving Credit Facility Availability | $350 million (no outstanding balance) | [Cash Flow from Operations](index=1&type=section&id=Cash%20Flow%20from%20Operations) Cash flows provided by operating activities decreased in Q2 2025 compared to the same period in 2024 Cash Flows from Operating Activities | Period | Amount | | :-------------------------------- | :----------- | | Q2 2025 | $43 million | | Q2 2024 | $59 million | [Corporate Highlights](index=1&type=section&id=Corporate%20Highlights) [Omnicell Illuminate 2025 Event](index=3&type=section&id=Omnicell%20Illuminate%202025%20Event) Omnicell's Illuminate 2025 event showcased best practices in pharmacy and nursing care technology, introducing new MedVision and MedTrack offerings - Hosted Omnicell Illuminate 2025, a hybrid event showcasing best practices for technology-driven pharmacy and nursing care[7](index=7&type=chunk)[9](index=9&type=chunk) - Announced new outcomes-centric offerings: MedVision and MedTrack/MedTrack - OR[9](index=9&type=chunk) [Innovation Lab Opening](index=3&type=section&id=Innovation%20Lab%20Opening) Omnicell opened a new Innovation Lab in Austin, Texas, to develop and test new healthcare solutions, coinciding with Illuminate 2025 - Grand opening of a new Innovation Lab in Austin, Texas, focused on developing and testing new solutions for the healthcare industry[13](index=13&type=chunk) [OmniSphere HITRUST CSF i1 Certification](index=3&type=section&id=OmniSphere%20HITRUST%20CSF%20i1%20Certification) OmniSphere, Omnicell's cloud-native software engine, achieved HITRUST CSF i1 certification in June 2025, demonstrating stringent healthcare security adherence - OmniSphere, the next-generation cloud-native software workflow engine and data platform, received **HITRUST CSF i1 certification** in June 2025[13](index=13&type=chunk) - This certification confirms adherence to **stringent security standards** in the healthcare sector[13](index=13&type=chunk) [IV TRUST Summit](index=3&type=section&id=IV%20TRUST%20Summit) Omnicell's inaugural IV TRUST Summit explored improving patient safety through automation and driving adoption of IV compounding automation - Hosted the inaugural IV TRUST Summit to explore improving patient safety through automation and drive adoption of IV compounding automation[13](index=13&type=chunk) [2025 Guidance](index=3&type=section&id=2025%20Guidance) [Q3 and Full Year 2025 Guidance Update](index=3&type=section&id=Q3%20and%20Full%20Year%202025%20Guidance%20Update) Omnicell reaffirmed 2025 product bookings and ARR outlook, while modestly increasing full-year guidance for total revenues, non-GAAP EBITDA, and EPS - Reaffirmed full-year 2025 product bookings and Annual Recurring Revenue outlook[10](index=10&type=chunk) - Modestly increased full-year 2025 guidance for **total revenues, non-GAAP EBITDA, and non-GAAP EPS**[10](index=10&type=chunk) Q3 and Full Year 2025 Guidance | Metric | Q3 2025 Guidance | Full Year 2025 Guidance | | :------------------------ | :------------------- | :---------------------- | | Product Bookings | Not provided | $500 million - $550 million | | Annual Recurring Revenue | Not provided | $610 million - $630 million | | Total Revenues | $290 million - $300 million | $1.130 billion - $1.160 billion | | Product Revenues | $165 million - $170 million | $625 million - $640 million | | Service Revenues | $125 million - $130 million | $505 million - $520 million | | Technical Services Revenues | Not provided | $245 million - $250 million | | SaaS and Expert Service Revenues | Not provided | $260 million - $270 million | | Non-GAAP EBITDA | $28 million - $32 million | $130 million - $145 million | | Non-GAAP Earnings Per Share | $0.30 - $0.37 | $1.40 - $1.65 | [Non-GAAP Guidance Disclaimer](index=3&type=section&id=Non-GAAP%20Guidance%20Disclaimer) Omnicell does not provide GAAP net income or EPS guidance, nor a reconciliation of forward-looking non-GAAP measures, due to unpredictable GAAP items - Company does not provide GAAP net income or EPS guidance due to the inability to predict certain significant GAAP items[11](index=11&type=chunk) [Company Information](index=4&type=section&id=Company%20Information) [About Omnicell](index=4&type=section&id=About%20Omnicell) Since 1992, Omnicell has transformed pharmacy and nursing care with solutions including robotics, smart devices, software, data analytics, and expert services - Omnicell transforms pharmacy and nursing care with solutions including robotics, smart devices, intelligent software, data analytics, and expert services[14](index=14&type=chunk) - Solutions aim to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and advance the Autonomous Pharmacy vision[14](index=14&type=chunk) [Investor Relations and Social Media Disclosure](index=4&type=section&id=Investor%20Relations%20and%20Social%20Media%20Disclosure) Omnicell may use its investor relations website and social media (LinkedIn, Facebook) to disclose material non-public information, complying with Reg FD - Company may use its investor relations website and social media (LinkedIn, Facebook) for disclosing material non-public information, adhering to Reg FD[15](index=15&type=chunk) [Trademarks](index=4&type=section&id=Trademarks) The press release includes trademarks of Omnicell and its subsidiaries, along with trademarks and service marks of other companies - OMNICELL and its logo are **registered trademarks** of Omnicell, Inc. or its subsidiaries[16](index=16&type=chunk) - Other trademarks and service marks mentioned belong to their respective owners[16](index=16&type=chunk) [Legal Disclosures](index=4&type=section&id=Legal%20Disclosures) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section identifies forward-looking statements subject to numerous risks and uncertainties, cautioning investors against undue reliance, with no obligation to update unless legally required - Statements using words like "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "believe," "forecast," "guidance," "outlook," "goals," "target," "estimate," "seek," "predict," "project," and similar expressions are forward-looking[17](index=17&type=chunk) - Forward-looking statements are subject to substantial known and unknown risks and uncertainties, including economic conditions, demand reduction, installation delays, international operations risks, and competition[17](index=17&type=chunk) - Investors are cautioned not to place undue reliance on these statements, and Omnicell assumes no obligation to update them publicly, except as required by law[18](index=18&type=chunk) [Use of Non-GAAP Financial Information](index=5&type=section&id=Use%20of%20Non-GAAP%20Financial%20Information) Omnicell uses non-GAAP financial measures to supplement GAAP results, providing insights into core operating performance and facilitating period-to-period comparisons [Management's Rationale for Non-GAAP Measures](index=5&type=section&id=Management%27s%20Rationale%20for%20Non-GAAP%20Measures) Management uses non-GAAP measures to evaluate performance, analyze strategy, and make operating decisions, as they provide supplemental information on core operating results - Management uses non-GAAP measures to evaluate performance, analyze strategy, and make operating decisions, as they provide supplemental information on core operating results[19](index=19&type=chunk)[20](index=20&type=chunk) - Non-GAAP measures exclude items whose magnitude and timing are largely outside Omnicell's control, are unrelated to ongoing operations, are unusual, or are non-operational/non-cash expenses[23](index=23&type=chunk) - Reasons for presentation include providing an additional analytical tool, ensuring consistency for investors, facilitating internal decision-making, and enabling comparisons to industry peers[24](index=24&type=chunk)[26](index=26&type=chunk) [Specific Non-GAAP Adjustments](index=5&type=section&id=Specific%20Non-GAAP%20Adjustments) This section details specific adjustments for non-GAAP reconciliation, including share-based compensation, acquired intangible amortization, and acquisition-related expenses - Non-GAAP adjustments include: * Share-based compensation expense (non-cash, not requiring cash settlement) * Amortization of acquired intangible assets (non-cash, not reflecting core cash-generating performance) * Acquisition-related expenses (unrelated to ongoing operations, variable) * Amortization of debt issuance costs (non-cash, not reflecting core cash-generating performance) * RDS restructuring charges (nonrecurring, primarily inventory write-down, severance) * Executives transition costs (unrelated to ongoing operations, non-recurring severance) * Legal and regulatory expenses (non-recurring settlement amounts for government contract claims) * Management severance costs (associated with senior leadership team restructuring)[20](index=20&type=chunk)[22](index=22&type=chunk)[25](index=25&type=chunk) [Limitations of Non-GAAP Financial Measures](index=8&type=section&id=Limitations%20of%20Non-GAAP%20Financial%20Measures) Non-GAAP measures have inherent limitations and should not be considered in isolation or as a substitute for GAAP results, as they may not be comparable across companies - Non-GAAP measures have limitations and should not be considered in isolation or as a substitute for GAAP results[28](index=28&type=chunk) - Limitations include: * Equity incentive plans are ongoing GAAP expenses * Other companies may calculate non-GAAP measures differently, limiting comparability * Free cash flow does not represent the total change in cash balance[30](index=30&type=chunk) [Non-GAAP Free Cash Flow Definition](index=8&type=section&id=Non-GAAP%20Free%20Cash%20Flow%20Definition) Non-GAAP free cash flow is net cash from operations minus capital expenditures, a key metric for evaluating ongoing operating results and financial performance - Non-GAAP free cash flow is defined as net cash provided by operating activities less cash used for software development for external use and purchases of property and equipment[27](index=27&type=chunk) - This metric is considered important for understanding and evaluating ongoing operating results and overall financial performance, as it accounts for necessary capital expenditures[27](index=27&type=chunk) [Condensed Consolidated Financial Statements](index=9&type=section&id=Condensed%20Consolidated%20Financial%20Statements) [Condensed Consolidated Statements of Operations](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The consolidated statements of operations detail revenues, costs, and expenses, showing Q2 2025 GAAP net income and a net loss for the six months ended June 30, 2025 Condensed Consolidated Statements of Operations (Three Months Ended June 30, in thousands) | Metric | 2025 (in thousands) | 2024 (in thousands) | | :-------------------------------- | :------------------ | :------------------ | | Product revenues | $163,172 | $156,580 | | Service revenues | $127,390 | $120,208 | | Total revenues | $290,562 | $276,788 | | Gross profit | $127,678 | $114,351 | | Income from operations | $8,120 | $3,224 | | Net income (loss) | $5,639 | $3,735 | | Diluted EPS | $0.12 | $0.08 | Condensed Consolidated Statements of Operations (Six Months Ended June 30, in thousands) | Metric | 2025 (in thousands) | 2024 (in thousands) | | :-------------------------------- | :------------------ | :------------------ | | Product revenues | $308,340 | $289,875 | | Service revenues | $251,890 | $233,064 | | Total revenues | $560,230 | $522,939 | | Gross profit | $238,614 | $206,974 | | Income (loss) from operations | $(3,499) | $(18,623) | | Net income (loss) | $(1,384) | $(11,941) | | Diluted EPS | $(0.03) | $(0.26) | [Condensed Consolidated Balance Sheets](index=10&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet provides a snapshot of assets, liabilities, and equity as of June 30, 2025, and December 31, 2024, showing increased total assets and stockholders' equity Condensed Consolidated Balance Sheets (in thousands) | Metric | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :-------------- | :---------------- | | Cash and cash equivalents | $399,004 | $369,201 | | Total current assets | $844,776 | $815,493 | | Total assets | $2,145,496 | $2,120,960 | | Total current liabilities | $594,392 | $595,678 | | Total liabilities | $881,877 | $877,647 | | Total stockholders' equity | $1,263,619 | $1,243,313 | [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) The cash flow statement details operating, investing, and financing activities for the six months ended June 30, 2025 and 2024, showing decreased operating cash and increased investing cash in 2025 Condensed Consolidated Statements of Cash Flows (Six Months Ended June 30, in thousands) | Activity | 2025 | 2024 | | :-------------------------------- | :--------- | :--------- | | Net cash provided by operating activities | $68,679 | $108,653 | | Net cash used in investing activities | $(31,662) | $(25,889) | | Net cash used in financing activities | $(7,431) | $(4,702) | | Net increase in cash, cash equivalents, and restricted cash | $32,886 | $77,260 | | Cash, cash equivalents, and restricted cash at end of period | $431,500 | $578,239 | [Reconciliation of GAAP to Non-GAAP Financial Measures](index=12&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Financial%20Measures) [Reconciliation of Gross Profit](index=12&type=section&id=Reconciliation%20of%20Gross%20Profit) This section reconciles GAAP to non-GAAP gross profit by adjusting for share-based compensation, acquired intangibles, and restructuring charges, resulting in higher non-GAAP gross profit and margin Reconciliation of Gross Profit (Three Months Ended June 30, in thousands) | Metric | 2025 | 2024 | | :-------------------------- | :--------- | :--------- | | GAAP gross profit | $127,678 | $114,351 | | Non-GAAP gross profit | $129,872 | $122,289 | | GAAP gross margin | 43.9% | 41.3% | | Non-GAAP gross margin | 44.7% | 44.2% | [Reconciliation of Operating Expenses](index=12&type=section&id=Reconciliation%20of%20Operating%20Expenses) This section reconciles GAAP to non-GAAP operating expenses by excluding non-cash and non-recurring items, leading to lower non-GAAP expenses and a reduced percentage of total revenues Reconciliation of Operating Expenses (Three Months Ended June 30, in thousands) | Metric | 2025 | 2024 | | :-------------------------------- | :--------- | :--------- | | GAAP operating expenses | $119,558 | $111,127 | | Non-GAAP operating expenses | $105,739 | $97,477 | | GAAP operating expenses % to total revenues | 41.1% | 40.1% | | Non-GAAP operating expenses as a % of total revenues | 36.4% | 35.2% | [Reconciliation of Income (Loss) from Operations](index=12&type=section&id=Reconciliation%20of%20Income%20(Loss)%20from%20Operations) This section reconciles GAAP to non-GAAP income from operations by adding back non-cash and non-recurring expenses, significantly improving operating income and margin Reconciliation of Income (Loss) from Operations (Three Months Ended June 30, in thousands) | Metric | 2025 | 2024 | | :-------------------------------- | :--------- | :--------- | | GAAP income (loss) from operations | $8,120 | $3,224 | | Non-GAAP income from operations | $24,133 | $24,812 | | GAAP operating income (loss) % to total revenues | 2.8% | 1.2% | | Non-GAAP operating margin | 8.3% | 9.0% | [Reconciliation of Net Income (Loss) and EPS](index=13&type=section&id=Reconciliation%20of%20Net%20Income%20(Loss)%20and%20EPS) This section reconciles GAAP net income (loss) and diluted EPS to non-GAAP equivalents by adjusting for non-cash, non-recurring items and their tax effects, resulting in higher non-GAAP net income and EPS Reconciliation of Net Income (Loss) and EPS (Three Months Ended June 30, in thousands, except per share data) | Metric | 2025 | 2024 | | :-------------------------------- | :--------- | :--------- | | GAAP net income (loss) | $5,639 | $3,735 | | Non-GAAP net income | $21,074 | $23,664 | | GAAP net income (loss) per share - diluted | $0.12 | $0.08 | | Non-GAAP net income per share - diluted | $0.45 | $0.51 | [Reconciliation of EBITDA](index=13&type=section&id=Reconciliation%20of%20EBITDA) This section reconciles GAAP net income (loss) to non-GAAP EBITDA by adding back interest, taxes, depreciation, amortization, share-based compensation, and other non-GAAP adjustments Reconciliation of EBITDA (Three Months Ended June 30, in thousands) | Metric | 2025 | 2024 | | :-------------------------------- | :--------- | :--------- | | GAAP net income (loss) | $5,639 | $3,735 | | Non-GAAP EBITDA | $38,375 | $39,849 | | Non-GAAP EBITDA margin | 13.2% | 14.4% | [Reconciliation of Free Cash Flow](index=15&type=section&id=Reconciliation%20of%20Free%20Cash%20Flow) This section reconciles GAAP net cash from operating activities to non-GAAP free cash flow by subtracting software development costs and property/equipment purchases Reconciliation of Free Cash Flow (Three Months Ended June 30, in thousands) | Metric | 2025 | 2024 | | :-------------------------------- | :--------- | :--------- | | GAAP net cash provided by operating activities | $42,755 | $58,700 | | Non-GAAP free cash flow | $26,832 | $45,151 |

Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Doximity (DOCS) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revis ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Omnicell, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Omnicell is expected to report quarterly earnings of $0.31 per share, reflecting a year-over-year decrease of 39.2% [3]. - Revenues are projected to be $276.76 million, indicating no change from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 42.1% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Omnicell currently holds a Zacks Rank of 4, complicating predictions for an earnings beat [12]. Historical Performance - In the last reported quarter, Omnicell exceeded expectations with earnings of $0.26 per share, a surprise of +62.50% [13]. - The company has beaten consensus EPS estimates in all of the last four quarters [14]. Market Reaction Considerations - An earnings beat or miss may not solely dictate stock movement, as other factors can influence investor sentiment [15]. - Omnicell does not appear to be a compelling candidate for an earnings beat, suggesting investors should consider additional factors before making decisions [17].

Company Vision and Strategy - Omnicell's mission is to be the care provider's most trusted partner, with a vision to accelerate pharmacy to perfection[10, 35] - The company aims to execute on the vision of a fully Autonomous Pharmacy, leveraging cloud technology to transform pharmacy care delivery[36, 116] - Omnicell differentiates itself through a comprehensive portfolio across the care continuum, serving 50% of US providers[36, 116] Market and Growth Opportunities - Omnicell estimates a total addressable market of $20 billion for Point of Care, $15 billion for Central Pharmacy, and significant opportunities in Retail, Institutional, and Payer segments over 10 years[43, 44] - The company projects revenue growth to $1450-$1550 million by 2024, driven by a ~17% CAGR in Central Pharmacy, ~10%-12% CAGR in Point of Care, and ~10% CAGR in Retail, Institutional, and Payer segments[110, 116] - Omnicell's XT Automated Dispensing Cabinets are early in their replacement cycle, showing 18% progress as of 3Q19[44] Financial Performance and Goals - Omnicell's revenue for 2019 is estimated to be between $889 and $895 million[106, 110, 128] - The company is committed to increasing non-GAAP operating margin to ~18% by 2024[108, 113, 116] - Omnicell targets a free cash flow conversion of 90%-110% of GAAP Net Income[115, 116] Medication Management and Safety - Medication errors lead to significant losses, including $300 billion annually, 1 million ER visits, and 125,000 hospitalizations[15] - A significant percentage of prescriptions, 20%-30%, are never filled, contributing to suboptimal outcomes[15] - Drug diversion costs $72.5 billion, highlighting the need for improved medication management and security[23]

Financial Performance & Guidance - Omnicell预计2020财年产品预订额约为10亿美元[7] - Omnicell预计2020财年总收入为8.9亿至8.92亿美元[7] - Omnicell预计2020财年Non-GAAP EBITDA为1.57亿至1.59亿美元[7] - Omnicell预计2020财年Non-GAAP每股收益为2.46至2.51美元[7] - Omnicell预计2021财年总收入为10.85亿至11.05亿美元[7] - Omnicell预计2021财年Non-GAAP EBITDA为2.28亿至2.4亿美元[7] - Omnicell预计2021财年Non-GAAP每股收益为3.38至3.58美元[7] Growth & Market Position - Omnicell在医疗保健数字化转型中占据领先地位，潜在市场规模超过700亿美元[7, 10] - Omnicell 目标是2021-2025年收入复合年增长率为14-15%（有机增长11-12%，无机增长3%）[7, 10] - Omnicell 目标是从2021-2025年Non-GAAP EBITDA利润率提高约400个基点[7, 10] - Omnicell 目标是SaaS、订阅软件和技术支持服务在2020-2025年的收入复合年增长率约为50%[7, 10]

Core Insights - Omnicell has launched new products, including RFID products under the MedTrack line and a web-enabled software named MedVision, aimed at improving medication management and workflow efficiency in healthcare settings [1][4][6] - The company’s market capitalization is currently $1.31 billion, with a projected revenue growth of 1.4% for 2025 according to Zacks Consensus Estimate [3] - The global Hospital Asset Tracking and Inventory Management Systems market is expected to reach $31.05 billion by 2025, growing at a CAGR of 5.5% through 2030, indicating a favorable industry environment for Omnicell [10] Company Developments - The MedTrack line includes MedTrack – OR, which is designed to enhance medication tracking in operating rooms and streamline workflows during surgical emergencies [5] - MedVision software facilitates real-time inventory management for outpatient clinics, allowing automatic reordering from central pharmacies when stock levels are low [6][7] - Omnicell has opened an Innovation Lab in Austin, Texas, to develop new technologies addressing challenges in medication and supply management [11] Market Sentiment - Following the product announcements, Omnicell shares remained stable in after-hours trading, with expectations that the new solutions will enhance market sentiment towards the stock [2] - Over the past three months, Omnicell shares have declined by 27.4%, contrasting with a 9.5% decline in the broader industry [12]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNI ...

Group 1 - The article highlights the focus on Omnicell, Inc. (OMCL), a small-cap medical technology solutions provider, which recently reported its Q1 results [2] - The Biotech Forum community discusses lucrative buy-write or covered call opportunities on selected biotech stocks, indicating a trend in investment strategies within the biotech sector [1] - The investing group led by Bret offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [2]

Core Viewpoint - Omnicell, Inc. reported strong first-quarter 2025 results with adjusted earnings per share (EPS) of 26 cents, significantly higher than the previous year's 3 cents, and exceeding the Zacks Consensus Estimate by 62.5% [1][9] Financial Performance - Revenues for Q1 2025 reached $269.7 million, reflecting a year-over-year increase of 9.6% and surpassing the Zacks Consensus Estimate by 4.2% [3] - Product revenues increased by 8.9% year over year to $145.2 million, while service and other revenues rose by 10.3% to $124.5 million [3] - Gross profit for the quarter was $110.9 million, up 19.8% year over year, with a gross margin expansion of 351 basis points to 41.1% despite a 3.4% rise in the cost of revenues [4] - Operating expenses were $122.6 million, a 7.1% increase year over year, leading to an operating loss of $11.6 million, improved from a loss of $21.8 million in the prior year [4] Cash Flow and Financial Position - At the end of Q1 2025, Omnicell had cash and cash equivalents of $386.8 million, up from $369.2 million at the end of Q4 2024 [5] - Net cash flow from operating activities was $25.9 million, down from $49.9 million in the same period last year [5] Future Outlook - For the full year 2025, total revenue is expected to be between $1.105 billion and $1.155 billion, with product revenues projected at $610 million to $640 million and service revenues at $495 million to $515 million [6] - The adjusted EPS guidance for 2025 has been revised down to a range of $1.00 to $1.65, compared to the previous guidance of $1.65 to $1.85 [7] - For Q2 2025, revenues are anticipated to be between $270 million and $280 million, with adjusted EPS expected to range from 19 cents to 32 cents [7] Strategic Developments - The company has seen growth driven by the XT Amplify program and increased contributions from SaaS and Expert Services, including Specialty Pharmacy Services [9] - Notable achievements in Q1 include the opening of the Austin Innovation Lab and partnerships with leading healthcare organizations to enhance pharmacy and nursing efficiency [10]